Nektar Therapeutics 公佈新的禿髮治療臨床試驗結果
Nektar Therapeutics reports on new alopecia treatment trial results
Nektar Therapeutics 最近分享了其REZOLVE-AA 第二b 期臨床試驗的結果，該試驗涉及治療嚴重圓禿（Alopecia areata）的新藥物rezpegaldesleukin（簡稱REZPEG）。
Nektar Therapeutics recently shared findings from its Phase 2b REZOLVE-AA trial involving rezpegaldesleukin (REZPEG), a new treatment for severe alopecia areata.
圓禿影響了2%的人口，常導致顯著的脫髮及情緒困擾。
Alopecia areata, which affects 2% of people, often leads to significant hair loss and emotional distress.
這項試驗測試了一種新穎的方法：藉由刺激調節性T細胞（Tregs）來平息免疫系統對毛囊的攻擊。
This trial tested a novel approach: stimulating regulatory T cells (Tregs) to calm the immune system's attack on hair follicles.
儘管初步分析未達到統計學上的顯著差異，但一項排除了不符合資格參與者的事後分析顯示，與僅有6%的安慰劑組相比，其頭皮脫髮減少了顯著的30%。
While the primary analysis narrowly missed significance, a post-hoc analysis excluding ineligible participants showed a notable 30% reduction in scalp hair loss compared to only 6% for the placebo.
該藥物看起來相當安全，極少有患者因副作用而停止治療。
The drug appears safe, with very few patients stopping treatment due to side effects.
儘管初始結果如此，FDA 已授予REZPEG「加速審查」資格，以認可對新療法的迫切需求。
Despite the initial results, the FDA has already granted REZPEG Fast Track designation, recognizing the urgent need for new therapies.
鑑於觀察到有望的毛髮再生效果，包括眉毛和睫毛的生長，Nektar 計畫推進第三期臨床試驗。
Given the promising hair regrowth observed, including in eyebrows and eyelashes, Nektar plans to move forward with Phase 3 testing.
這項進展為患有此慢性病症的患者帶來希望，因為現有的治療方法往往伴隨高復發率。
This development offers hope for those suffering from this chronic condition, as current treatments often come with high relapse rates.
